PUBLISHER: Grand View Research | PRODUCT CODE: 1446514
PUBLISHER: Grand View Research | PRODUCT CODE: 1446514
The global androgenetic alopecia market size is anticipated to reach USD 4.76 billion by 2030 and is anticipated to expand at a CAGR of 8.45% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of androgenetic alopecia is one of the crucial factors driving the market growth. According to data published by the American Hair Loss Association, over 95% of hair loss in men is caused due to androgenetic alopecia. The occurrence of hair loss in men increases proportionately with age. On the basis of the report published by the International Society of Hair Restoration Surgery, in men, it is estimated that 40% of hair loss is encountered by the age of 35 years, 65% at 60 years, 70% at 80 years, and 80% at the age of 85 years.
Moreover, the market growth can be attributed to advancements in technology, including the introduction of a low-level laser therapy, which helps stimulate hair growth. Likewise, the introduction of several laser combs and hair massagers or brushes is also boosting the market. For instance, Lifemax Infrared Hairbrush, Follinex Massager Comb, and Hairmax Laser Comb are some of the technologically advanced products available in the market. Most clinical-based settings offer combination therapy of non-ablative laser treatment and topical application of medicinal products for better results. Microscopic injuries created by laser devices create a favorable wound-healing environment that triggers hair regrowth.
Furthermore, the increasing incidence of chronic diseases such as cancer is anticipated to offer lucrative opportunities for market growth. For instance, according to the latest report by Globocan, the incidence of cancer was estimated to be 19,288,916 in 2020 globally. Certain medications prescribed to patients for the treatment of cancer are also responsible for hair loss. For instance, chemotherapeutic agents, radiation therapy, hormone therapy, and immunotherapy are more likely to induce hair loss or hair thinning. Cancer incidence is expected to rise by about 70% over the next two decades, thus driving the market growth.
However, reimbursement coverage for androgenetic alopecia treatment is one of the major challenges in this market. Since most treatment modalities for AGA are considered cosmetic procedures and not medically essential ones, they are generally not covered under insurance. Out-of-pocket costs for AGA treatment usually include frequent doctor visits, prescription drug copays, and coinsurance for procedures. Alopecia has complex reimbursement positioning, as it is not a life-threatening disease. For instance, Aetna Inc.'s policy for alopecia states that drugs covered for mild conditions are different from those considered for more severe conditions. In addition, the scheme does not cover Rogaine (minoxidil) as it is considered an experimental therapy. Thus, lack of reimbursement policies for treatment is restraining the market growth.